{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:09:35Z","timestamp":1792760975188,"version":"4.5.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In patients undergoing percutaneous coronary intervention (PCI), the use of anti-inflammatory therapy with colchicine is associated with a reduction of recurrent ischemic events. The mechanisms of such findings are not fully elucidated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To investigate the effects of colchicine versus aspirin on inflammation and platelet reactivity in patients with acute coronary syndrome (ACS) undergoing PCI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This observational study compared laboratory measurements in ACS patients receiving single antiplatelet therapy with ticagrelor or prasugrel plus colchicine (MACT) (<jats:italic>n<\/jats:italic>\u2009=\u2009185) versus conventional dual-antiplatelet therapy (DAPT) with aspirin plus ticagrelor or prasugrel (<jats:italic>n<\/jats:italic>\u2009=\u2009497). The primary outcome was the frequency of high residual inflammation, defined as high-sensitivity C-reactive protein (hs-CRP) \u22652\u2009mg\/L at 1\u2009month post-PCI. Multiple sensitivity analyses were performed for the primary outcome, including multivariable adjustment, propensity-score matching, and inverse-probability weighted methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One month after PCI, patients treated with MACT had significantly lower levels of hs-CRP compared to those treated with DAPT (0.6 [0.4\u20131.2] vs. 0.9 [0.6\u20132.3] mg\/L, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). The frequency of high residual inflammation was also lower in the MACT group (10.8% vs. 27.2%, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001) (odds ratio [95% confidence interval]\u2009=\u20090.33 [0.20\u20130.54], <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). This effect was consistent across sensitivity analyses. There was no difference in platelet reactivity between MACT and DAPT (49.6\u2009\u00b1\u200949.0 vs. 51.5\u2009\u00b1\u200966.4 P2Y<jats:sub>12<\/jats:sub> reaction unit [PRU] measured by VerifyNow, <jats:italic>p<\/jats:italic>\u2009=\u20090.776).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In ACS patients undergoing PCI, MACT was associated with a lower rate of high residual inflammation without increasing platelet reactivity compared to conventional DAPT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p>NCT04949516 for MACT pilot trial and NCT04650529 for Gyeongsang National University Hospital registry.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1349577","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T04:51:11Z","timestamp":1715835071000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Inflammation and platelet reactivity during adjunctive colchicine versus aspirin in patients with acute coronary syndrome treated with potent P2Y12 inhibitor"],"prefix":"10.3389","volume":"11","author":[{"given":"Seung-Yul","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Young","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana A.","family":"Gorog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeong Ho","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Hwa","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sin","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwhi","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Jae","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yong","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangsoo","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Hoon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of Clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: The STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jacc.2015.06.1323","article-title":"Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention","volume":"66","author":"Genereux","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/j.jacc.2017.02.029","article-title":"Bleeding-related deaths in relation to the duration of dual-antiplatelet therapy after coronary stenting","volume":"69","author":"Palmerini","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcin.2022.10.023","article-title":"Timing, selection, modulation, and duration of P2Y(12) inhibitors for patients with acute coronary syndromes undergoing PCI","volume":"16","author":"Capodanno","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","article-title":"Bleeding avoidance strategies in percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41569-023-00901-2","article-title":"De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a consensus statement from an international expert panel on coronary thrombosis","volume":"20","author":"Gorog","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the academic research consortium","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1093\/eurheartj\/ehy633","article-title":"Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions","volume":"39","author":"Kalkman","year":"2018","journal-title":"Eur Heart J"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.jacc.2019.01.077","article-title":"Residual inflammatory risk in patients with low LDL cholesterol levels undergoing percutaneous coronary intervention","volume":"73","author":"Guedeney","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/jamacardio.2019.0179","article-title":"Association of initial and serial C-reactive protein levels with adverse cardiovascular events and death after acute coronary syndrome: a secondary analysis of the VISTA-16 trial","volume":"4","author":"Mani","year":"2019","journal-title":"JAMA Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1093\/eurheartj\/ehaa659","article-title":"Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT)","volume":"41","author":"Bouabdallaoui","year":"2020","journal-title":"Eur Heart J"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"175068","DOI":"10.1016\/j.ejphar.2022.175068","article-title":"Effect of colchicine on inflammatory markers in patients with coronary artery disease: a meta-analysis of clinical trials","volume":"927","author":"Pan","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/MCA.0000000000001220","article-title":"Meta-analysis of the effect of colchicine on C-reactive protein in patients with acute and chronic coronary syndromes","volume":"34","author":"Alam","year":"2023","journal-title":"Coron Artery Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1093\/eurheartj\/ehab221","article-title":"Colchicine and the heart","volume":"42","author":"Imazio","year":"2021","journal-title":"Eur Heart J"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1055\/s-0042-1749660","article-title":"Colchicine as a modulator of platelet function: a systematic review","volume":"48","author":"Reddel","year":"2022","journal-title":"Semin Thromb Hemost"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jcin.2023.05.035","article-title":"P2Y(12) inhibitor monotherapy combined with colchicine following PCI in ACS patients: The MACT pilot study","volume":"16","author":"Lee","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/eurheartj\/ehad088","article-title":"Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction","volume":"44","author":"Lee","year":"2023","journal-title":"Eur Heart J"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with Canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1538-7836.2010.04160.x","article-title":"In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation","volume":"9","author":"Armstrong","year":"2011","journal-title":"J Thromb Haemost"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3109\/09537104.2012.748185","article-title":"Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers","volume":"24","author":"Teng","year":"2013","journal-title":"Platelets"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.jcin.2020.06.023","article-title":"Aspirin-free Prasugrel monotherapy following coronary artery stenting in patients with stable CAD: The ASET pilot study","volume":"13","author":"Kogame","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4244\/EIJ-D-22-00886","article-title":"Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study","volume":"19","author":"van der Sangen","year":"2023","journal-title":"EuroIntervention"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/s41569-022-00725-6","article-title":"P2Y(12) inhibitor monotherapy in patients undergoing percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jacasi.2021.11.014","article-title":"Residual inflammatory risk and its association with events in east Asian patients after coronary intervention","volume":"2","author":"Ahn","year":"2022","journal-title":"JACC Asia"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ahj.2019.06.003","article-title":"The low dose colchicine after myocardial infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction","volume":"215","author":"Hennessy","year":"2019","journal-title":"Am Heart J"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s10787-021-00865-0","article-title":"Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial","volume":"29","author":"Gholoobi","year":"2021","journal-title":"Inflammopharmacology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.121.056171","article-title":"Colchicine in cardiovascular disease: in-depth review","volume":"145","author":"Deftereos","year":"2022","journal-title":"Circulation"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/ehjcvp\/pvad005","article-title":"The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes","volume":"9","author":"Johansen","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jcmg.2017.08.013","article-title":"Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study","volume":"11","author":"Vaidya","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.ahj.2007.03.019","article-title":"Human epicardial adipose tissue: a review","volume":"153","author":"Sacks","year":"2007","journal-title":"Am Heart J"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.vph.2018.09.004","article-title":"Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1","volume":"111","author":"Cimmino","year":"2018","journal-title":"Vasc Pharmacol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"11965","DOI":"10.1038\/s41598-021-91409-7","article-title":"Colchicine inhibits ROS generation in response to glycoprotein VI stimulation","volume":"11","author":"Pennings","year":"2021","journal-title":"Sci Rep"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3109\/09537100903548903","article-title":"Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the thrombotic RIsk progression (TRIP) study","volume":"21","author":"Tantry","year":"2010","journal-title":"Platelets"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1080\/09537104.2018.1457782","article-title":"Systemic inflammatory status is associated with increased platelet reactivity in the early period after acute coronary syndromes","volume":"29","author":"Cornara","year":"2018","journal-title":"Platelets"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"736466","DOI":"10.3389\/fcvm.2021.736466","article-title":"Similar inflammatory biomarkers reflect different platelet reactivity in percutaneous coronary intervention patients treated with Clopidogrel: a large-sample study from China","volume":"8","author":"Li","year":"2021","journal-title":"Front Cardiovasc Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1349577\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T11:50:26Z","timestamp":1726055426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1349577\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":41,"alternative-id":["10.3389\/fmed.2024.1349577"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1349577","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]},"article-number":"1349577"}}